132 related articles for article (PubMed ID: 34662828)
1. Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457.
Sulima A; Akhlaghi F; Leggio L; Rice KC
Bioorg Med Chem; 2021 Nov; 50():116465. PubMed ID: 34662828
[TBL] [Abstract][Full Text] [Related]
2. Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.
Adusumalli S; Jamwal R; Obach RS; Ryder TF; Leggio L; Akhlaghi F
Drug Metab Dispos; 2019 Aug; 47(8):874-882. PubMed ID: 31182423
[TBL] [Abstract][Full Text] [Related]
3. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.
Lee MR; Tapocik JD; Ghareeb M; Schwandt ML; Dias AA; Le AN; Cobbina E; Farinelli LA; Bouhlal S; Farokhnia M; Heilig M; Akhlaghi F; Leggio L
Mol Psychiatry; 2020 Feb; 25(2):461-475. PubMed ID: 29728704
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of an assay for a novel ghrelin receptor inverse agonist PF-5190457 and its major hydroxy metabolite (PF-6870961) by LC-MS/MS in human plasma.
Adusumalli S; Jamwal R; Leggio L; Akhlaghi F
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Nov; 1130-1131():121820. PubMed ID: 31670107
[TBL] [Abstract][Full Text] [Related]
5. Initial Pharmacological Characterization of a Major Hydroxy Metabolite of PF-5190457: Inverse Agonist Activity of PF-6870961 at the Ghrelin Receptor.
Deschaine SL; Hedegaard MA; Pince CL; Farokhnia M; Moose JE; Stock IA; Adusumalli S; Akhlaghi F; Hougland JL; Sulima A; Rice KC; Koob GF; Vendruscolo LF; Holst B; Leggio L
J Pharmacol Exp Ther; 2023 Aug; 386(2):117-128. PubMed ID: 36631279
[TBL] [Abstract][Full Text] [Related]
6. Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor.
Kalgutkar AS; Ryder TF; Walker GS; Orr ST; Cabral S; Goosen TC; Lapham K; Eng H
Drug Metab Dispos; 2013 Jul; 41(7):1375-88. PubMed ID: 23610086
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the first in class clinical candidate PF-05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose-dependent insulin secretion ex vivo.
Kong J; Chuddy J; Stock IA; Loria PM; Straub SV; Vage C; Cameron KO; Bhattacharya SK; Lapham K; McClure KF; Zhang Y; Jackson VM
Br J Pharmacol; 2016 May; 173(9):1452-64. PubMed ID: 26784385
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers.
Lee MR; Farokhnia M; Cobbina E; Saravanakumar A; Li X; Battista JT; Farinelli LA; Akhlaghi F; Leggio L
Neuropharmacology; 2020 Jun; 170():107788. PubMed ID: 31557492
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.
Denney WS; Sonnenberg GE; Carvajal-Gonzalez S; Tuthill T; Jackson VM
Br J Clin Pharmacol; 2017 Feb; 83(2):326-338. PubMed ID: 27621150
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
Li H; Anderes KL; Kraynov EA; Luthin DR; Do QQ; Hong Y; Tompkins E; Sun ET; Rajapakse R; Pathak VP; Christie LC; Feng J; Vazir H; Castillo R; Gregory ML; Castro M; Nared-Hood K; Paderes G; Anderson MB
J Med Chem; 2006 Jun; 49(11):3362-7. PubMed ID: 16722655
[TBL] [Abstract][Full Text] [Related]
11. Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor.
Kung DW; Coffey SB; Jones RM; Cabral S; Jiao W; Fichtner M; Carpino PA; Rose CR; Hank RF; Lopaze MG; Swartz R; Chen HT; Hendsch Z; Posner B; Wielis CF; Manning B; Dubins J; Stock IA; Varma S; Campbell M; DeBartola D; Kosa-Maines R; Steyn SJ; McClure KF
Bioorg Med Chem Lett; 2012 Jul; 22(13):4281-7. PubMed ID: 22677316
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological profile of a new selective G protein-coupled receptor 119 agonist; 6-((2-fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one.
Sakairi M; Kogami M; Torii M; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
Chem Pharm Bull (Tokyo); 2012; 60(9):1093-5. PubMed ID: 22976315
[TBL] [Abstract][Full Text] [Related]
13. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor.
Holst B; Frimurer TM; Mokrosinski J; Halkjaer T; Cullberg KB; Underwood CR; Schwartz TW
Mol Pharmacol; 2009 Jan; 75(1):44-59. PubMed ID: 18923064
[TBL] [Abstract][Full Text] [Related]
14. 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.
Shukla L; Ajram LA; Begg M; Evans B; Graves RH; Hodgson ST; Lynn SM; Miah AH; Percy JM; Procopiou PA; Richards SA; Slack RJ
Eur J Med Chem; 2016 Jun; 115():14-25. PubMed ID: 26991939
[TBL] [Abstract][Full Text] [Related]
15. A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers.
Cobbina E; Lee MR; Leggio L; Akhlaghi F
Clin Pharmacokinet; 2021 Apr; 60(4):471-484. PubMed ID: 33155163
[TBL] [Abstract][Full Text] [Related]
16. Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and dasatinib.
Li W; Josephs JL; Skiles GL; Humphreys WG
Drug Metab Dispos; 2008 Apr; 36(4):721-30. PubMed ID: 18227141
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 2,3-dihydro-5,6-dimethoxy-1H-inden-1-one and piperazinium salt hybrid derivatives as hAChE and hBuChE enzyme inhibitors.
Mozaffarnia S; Teimuri-Mofrad R; Rashidi MR
Eur J Med Chem; 2020 Apr; 191():112140. PubMed ID: 32088494
[TBL] [Abstract][Full Text] [Related]
18. Simple approach to thieno[3,2-d]pyrimidines as new scaffolds of antimicrobial activities.
Hafez HN; El-Gazzar AR; Zaki ME
Acta Pharm; 2016 Sep; 66(3):331-51. PubMed ID: 27383884
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of 5-(4-alkylsulfanyl-[1, 2, 5]thiadiazol-3-yl)-3-methyl-1, 2, 3, 4-tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists.
Jung MH; Park JG; Park WK
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):230-5. PubMed ID: 12916057
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
Cai J; Zhang S; Zheng M; Wu X; Chen J; Ji M
Bioorg Med Chem Lett; 2012 Jan; 22(2):806-10. PubMed ID: 22217877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
